Corvus Pharmaceuticals In... (CRVS)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
5.00
0.27 (5.71%)
At close: Jan 17, 2025, 3:59 PM
5.01
0.10%
After-hours Jan 17, 2025, 04:00 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 151.00K | 367.00K | 460.00K | 632.00K | 743.00K | 847.00K | 842.00K | 594.00K | 148.00K | n/a |
Gross Profit | -151.00K | -367.00K | -460.00K | -632.00K | -743.00K | -847.00K | -842.00K | -594.00K | -148.00K | n/a |
Operating Income | -23.41M | -32.56M | -38.63M | -43.76M | -48.85M | -49.22M | -56.52M | -36.98M | -13.77M | -175.64K |
Interest Income | n/a | 654.00 | n/a | 540.00K | 2.18M | 2.28M | 861.00K | 601.00K | 35.00K | n/a |
Pretax Income | -27.03M | -41.31M | -43.24M | -6.00M | -46.67M | -46.94M | -55.66M | -36.38M | -31.34M | -175.64K |
Net Income | -27.03M | -50.05M | -38.20M | -4.82M | -43.75M | -46.94M | -55.66M | -36.38M | -31.34M | -175.64K |
Selling & General & Admin | 6.73M | 8.10M | 9.52M | 11.93M | 10.88M | 10.64M | 10.22M | 7.62M | 2.42M | 134.18K |
Research & Development | 16.53M | 24.47M | 29.11M | 31.83M | 37.98M | 38.59M | 46.30M | 29.36M | 11.35M | 41.45K |
Other Expenses | n/a | 587.00K | 235.00K | 37.46M | n/a | n/a | n/a | n/a | -17.60M | n/a |
Operating Expenses | 23.26M | 32.56M | 38.63M | 43.76M | 48.85M | 49.22M | 56.52M | 36.98M | 13.77M | 175.64K |
Interest Expense | 1.58M | 654.00K | 15.00K | 540.00K | 2.18M | 2.28M | n/a | 601.00K | n/a | n/a |
Selling & Marketing Expenses | -151.00K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 23.41M | 32.56M | 38.63M | 43.76M | 48.85M | 49.22M | 56.52M | 36.98M | 13.77M | 175.64K |
Income Tax | n/a | 8.74M | -5.04M | -1.17M | -2.92M | 2.28M | -842.00K | -594.00K | -35.00K | n/a |
Shares Outstanding (Basic) | 48.03M | 46.55M | 41.85M | 29.48M | 29.35M | 27.51M | 20.49M | 15.42M | 20.41M | 170.00K |
Shares Outstanding (Diluted) | 48.03M | 46.55M | 41.85M | 29.48M | 29.35M | 27.51M | 20.49M | 15.42M | 20.41M | 170.28K |
EPS (Basic) | -0.56 | -1.08 | -0.91 | -0.16 | -1.49 | -1.71 | -2.72 | -2.36 | -1.54 | -1.03 |
EPS (Diluted) | -0.56 | -1.08 | -0.91 | -0.16 | -1.49 | -1.71 | -2.72 | -2.36 | -1.54 | -1.03 |
EBITDA | -26.88M | -40.94M | -42.78M | -5.36M | -48.85M | -46.09M | -54.82M | -35.78M | -31.19M | 14.64K |
Depreciation & Amortization | 151.00K | 367.00K | 460.00K | 632.00K | 743.00K | 847.00K | 842.00K | 594.00K | 148.00K | 175.64K |